BMS delivered a targeted performance boost in multiple myeloma cell therapy with new data for its BCMA CAR T, arlocabtagene autoleucel, in the QUINTESSENTIAL study. The trial met its overall response and complete response improvements in a heavily pretreated population, and analysts characterized the update as a “key derisking event” ahead of FDA review timelines. On manufacturing infrastructure, Teijin, Teijin Regenet, and Shinshu University Hospital agreed to collaborate on CAR T manufacturing technologies under a joint research agreement. The initiative focuses on strengthening Japan’s cell and gene therapy manufacturing base through quality-management expertise, quality testing methods, and the use of Shinshu University Hospital’s Cell Processing Center to explore automation and efficiency improvements. The combined clinical-plus-operational updates show cell therapy momentum moving on both fronts: efficacy refinement for specific patient exposures and broader scale readiness for next-wave delivery.